{"id":"NCT04285580","sponsor":"AbbVie","briefTitle":"A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension","officialTitle":"An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-11","primaryCompletion":"2022-05-14","completion":"2022-05-14","firstPosted":"2020-02-26","resultsPosted":"2023-06-08","lastUpdate":"2023-06-08"},"enrollment":37,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Bimatoprost SR","otherNames":[]},{"type":"DRUG","name":"LUMIGAN","otherNames":[]}],"arms":[{"label":"Bimatoprost SR 10 μg","type":"EXPERIMENTAL"},{"label":"LUMIGAN 0.01%","type":"OTHER"}],"summary":"This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension","primaryOutcome":{"measure":"Change From Baseline in Time-Matched Intraocular Pressure (IOP) for Bimatoprost SR Treated Eyes","timeFrame":"8 weeks","effectByArm":[{"arm":"Bimatoprost SR 10 μg","deltaMin":-3.7,"sd":5.65},{"arm":"LUMIGAN 0.01%","deltaMin":-4,"sd":5.27}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["37343625"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["CONJUNCTIVAL HYPERAEMIA","INTRAOCULAR PRESSURE INCREASED","CONJUNCTIVAL HAEMORRHAGE","VISUAL FIELD DEFECT","CATARACT"]}}